Race Oncology Limited (ASX:RAC)
Australia flag Australia · Delayed Price · Currency is AUD
3.130
+0.020 (0.64%)
Sep 26, 2025, 4:10 PM AEST
0.64%
Market Cap544.00M
Revenue (ttm)6.04M
Net Income (ttm)-4.79M
Shares Out173.80M
EPS (ttm)-0.03
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume376,449
Average Volume669,818
Open3.100
Previous Close3.110
Day's Range3.060 - 3.270
52-Week Range0.920 - 3.570
Beta1.94
RSI76.89
Earnings DateNov 25, 2025

About Race Oncology

Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments. The company’s lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients. It is advancing reformulated bisantrene (RC220) to address the unmet need of patients across various oncology indications with a clinical focus on anthracycline combination to deliver cardioprotection and enhanced anticancer... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol RAC
Full Company Profile

Financial Performance

In 2025, Race Oncology's revenue was 6.04 million, an increase of 24.96% compared to the previous year's 4.84 million. Losses were -4.79 million, -65.36% less than in 2024.

Financial Statements

News

There is no news available yet.